Bruker Corporation - BRKR STOCK NEWS

Bruker Corporation has completed the acquisition of ZONTAL Inc., a platform provider for the digital transformation of the analytical laboratory. The acquisition strengthens Bruker BioSpin's software division and enables integrated digital laboratory and process data management. ZONTAL expects revenues of over $5 million in 2023.

Bruker Corporation announces Q1 2023 revenues of $685.3 million, up 15.2% YoY, with organic revenue growth of 17.6% YoY. GAAP EPS is $0.52 and non-GAAP EPS is $0.64, up 30.6% YoY. FY 2023 revenue guidance increased to $2.83-$2.88 billion, implying 12%-14% growth and organic revenue growth of 9%-11% YoY. Non-GAAP EPS guidance raised to $2.55-$2.60, representing 9%-11% YoY growth.

Bruker Corporation (NASDAQ: BRKR) will report its first quarter 2023 financial results on May 4, 2023, before market opening. A conference call and webcast will follow at 8:30 a.m. Eastern Time to discuss the results and current business trends. Investors can listen to the webcast via the company's investor relations website or by phone. Pre-registration is available for the call to streamline entry. A telephone replay of the conference will be accessible from one hour after the call until June 4, 2023, using a specified access code. Bruker continues to focus on enabling scientists to drive advancements and innovations in various scientific fields.

Bruker Corporation recently showcased its latest innovations in NMR spectroscopy at the Experimental Nuclear Magnetic Resonance Conference (ENC 2023). The highlight is the launch of the Ascend Evo 400, a new 400 MHz NMR magnet with a liquid helium hold-time of one year. This advancement reduces ownership costs and enhances operational convenience.

The Ascend Evo 1.0 GHz system, featuring a 65% reduction in liquid helium consumption, is utilized in prestigious labs like the RIKEN Center in Japan. The release also discusses the HelioSmart-R system, which recovers helium gas, and the new Fourier 80 platform for battery and pharmaceutical research.

Bruker emphasizes its commitment to sustainability and advancing cleantech research, highlighting collaborations with key industry players.

Bruker Corporation (Nasdaq: BRKR) has announced its latest innovations in diagnostic solutions at the 33rd European Congress of Clinical Microbiology & Infectious Diseases. Key highlights include:

• MBT Mycobacteria IVD Kit: Optimizes sample preparation for reliable identification of nontuberculous mycobacteria.
• MBT HT Filamentous Fungi IVD Module: Features an extensive fungal library for high identification success rates.
• MBT Compass HT IVD Software: Enhances microbial identification speed with automated self-tuning, analyzing up to 600 samples per hour.
• LiquidArray® Gastrointestinal PCR Panel: Detects 26 pathogens causing gastroenteritis, streamlining workflows for clinical laboratories.

Dr. Wolfgang Pusch noted that these advancements provide valuable solutions for clinical microbiology labs, enhancing pathogen coverage and identification efficiency.

At the AACR Annual Meeting 2023, PreOmics launched a new BeatBox-based FFPE workflow aimed at enhancing tissue proteomics applications. This workflow allows high-throughput processing of up to 96 FFPE samples simultaneously, streamlining protocol by eliminating the need for xylene-based deparaffinization. The BeatBox system ensures fast processing, typically within 10 minutes, with a demonstrated increase in proteomic depth of 14% to 43% compared to traditional methods. Bruker Corporation will co-commercialize this innovative workflow alongside its timsTOF Pro mass spectrometer. With significant time savings and improved reproducibility, this development is poised to facilitate large-scale biobank projects and enhance research efficiency in pathology.

Canopy Biosciences and Enable Medicine have partnered to enhance the Canopy CellScape system for spatial biology through advanced analysis and cloud-based analytics. This collaboration integrates Enable's analysis tools, including cluster and neighborhood analysis, into the CellScape system, which allows for the detection of multiple protein targets and facilitates high-plex spatial proteomics.

The partnership aims to streamline data analysis for research applications, promising to enhance quantitative insights and discovery capabilities in spatial biology. This integrated data workflow will be showcased at the upcoming AACR annual meeting in April 2023.

Bruker Corporation announces the delivery of two 1.2 GHz Avance nuclear magnetic resonance (NMR) spectrometers to the University of Warwick and the University of Birmingham in the UK. These advanced instruments will enhance capabilities in research areas including energy storage, biofuels, and biomolecule structures. Expected installations in 2025 aim to empower UK scientists and students with state-of-the-art research tools. This initiative supports breakthroughs in renewable energy technologies and drug discovery, specifically targeting antibiotic resistance.